Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study
Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study
复制标题
DOI：
10.1007/s00280-010-1403-0
复制
发表时间：
2010-11-01
影响因子：
3
通讯作者：
van den Brule, Adriaan J. C.
中科院分区：
文献类型：
--
作者：
Farina-Sarasqueta, Arantza;van Lijnschoten, Gesina;van den Brule, Adriaan J. C.
药物遗传学在结肠癌化疗反应中的作用存在争议。我们研究了参与5-FU代谢的基因中已知的SNP作为III期结肠癌患者化疗反应生物标志物的价值。从60例接受5-FU联合亚叶酸辅助治疗的III期结肠癌患者的正常结肠组织中分离DNA。测试的 SNP 是 OPRT、TYMS 和 DPYD 基因上经过验证的 SNP，以及 TYMP 基因上的同义 SNP。使用实时 PCR、测序和 RFLP 进行基因分型。所研究的基因型均与任何肿瘤或患者特征无关。此外，所研究的基因型均不影响患者的生存。 总之，所测试的 SNP 并不是我们的 III 期结肠癌患者组中化疗反应的生物标志物。
The role of pharmacogenetics in chemotherapy response in colon carcinoma is controversial. We studied the value of known SNPs in genes involved in 5-FU metabolism as biomarkers of chemotherapy response in patients with stage III colon carcinoma.DNA was isolated from normal colonic tissue of 60 patients with stage III colon carcinoma treated adjuvantly with 5-FU combined with leucovorin. The tested SNPs were validated SNPs on the OPRT, TYMS and DPYD genes and a synonymous SNP on the TYMP gene. Real-time PCR, sequencing and RFLP were used for genotyping.None of the studied genotypes was associated with any of the tumor or patient characteristics. Moreover, none of the genotypes studied had effect on patient survival.In conclusion, the tested SNPs are not biomarkers of chemotherapy response in our stage III colon cancer patients group.